Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

M. Luinstra, A.W.F. Rutgers, T. van Laar, F. Grasmeijer, A. Begeman, V. Isufi, L. Steenhuis, P. Hagedoorn, A.H. de Boer, H.W. Frijlink

  • Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease, Therapeutic Advances in Chronic Disease,
  • 2019,
  • 10

More info

SHARE THIS POST